Compare CERS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERS | ABEO |
|---|---|---|
| Founded | 1991 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 281.0M |
| IPO Year | 1997 | 1980 |
| Metric | CERS | ABEO |
|---|---|---|
| Price | $1.99 | $5.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $18.20 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $199,191,000.00 | $400,000.00 |
| Revenue This Year | $25.31 | N/A |
| Revenue Next Year | $9.50 | $1,589.77 |
| P/E Ratio | ★ N/A | $4.10 |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.12 | $3.93 |
| 52 Week High | $2.26 | $7.54 |
| Indicator | CERS | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 55.21 |
| Support Level | $1.99 | $5.11 |
| Resistance Level | $2.12 | $5.55 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 5.17 | 69.08 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.